Rejuvenation therapies
Phil Newman
Editor-In-Chief, Longevity.Technology
Review of Day 1 in the context of rejuvenation therapies and introductions.
Jamie Metzl
Author, Technology Futurist
Scene-setter and session introduction
Aubrey de Grey
Founder and CEO, SENS Foundation
The divide-and-conquer nature of rejuvenation can be an asset, not a challenge
Nir Barzilai
Director, Institute for Aging Research
How do we show in humans that a drug targets aging?
Ilaria Bellantuono
Professor in Musculoskeletal Ageing, Co-Director, The Healthy Lifespan Institute, Department of Oncology and Metabolism
Geroprotectors: time to change the way we treat older people?
Gary Hudson
Executive Chairman, Oisín Biotechnologies
Removal of senescent cells to extend healthspan & lifespan
Reason
Co-founder and CEO Repair Biotechnologies & Fight Aging!
The undeveloped hinterland of rejuvenation
Nina Khera
Co-Founder, Biotein
Group discussion with various Day 2 speakers
Nina Khera
Co-Founder, Biotein
Finding novel therapies for zombie cells using Artificial Intelligence
Michael D West
Chief Executive Officer, AgeX Therapeutics
Supercentenarians – reprogramming cells (TBC)
Joan Mannick
Chief Medical Officer, resTORbio
The use of TORC1 inhibitors to improve immune function in the elderly
Vadim Gladyshev
Professor of Medicine and Director, Center for Redox Medicine, Brigham and Women’s Hospital, Harvard Medical School, USA
From Longevity signatures to Longevity interventions
João Pedro de Magalhães
Senior Lecturer, University of Liverpool
Anti-aging biotech: past, present and future
Bryant Villeponteau
Chairman and Chief Scientific Officer, Centagen, Inc.
Rejuvenated stem cells to reverse aging
Jamie Metzl
Author, Technology Futurist
Review of content and group discussion